Printer Friendly

Elsevier Collaborates with Beijing University of Chinese Medicine to Build Taxonomy for Traditional Chinese Medicine in Embase Datebase.

M2 PHARMA-March 1, 2018-Elsevier Collaborates with Beijing University of Chinese Medicine to Build Taxonomy for Traditional Chinese Medicine in Embase Datebase

(C)2018 M2 COMMUNICATIONS

- Amsterdam, The Netherlands-based digital solutions provider Elsevier is working with Beijing University of Chinese Medicine (BUCM) to create a new taxonomy for traditional Chinese medicine (TCM) in the biomedical literature database, Embase, the company said.

During the six-month collaboration, BUCM will review terms and help build a detailed, robust taxonomy to encompass all TCM data in Embase.

The taxonomy will enrich and enhance the existing content in Embase; making it easily discoverable to users seeking knowledge from clinical practices for modern biomedical sciences.

Although TCM literature from the historical period and from modern clinical studies has recently been digitized in relational databases or text documents, searching and retrieving the precise evidence using abstract and indexing databases remains a challenge.

Further, TCM relies on numerous spellings, synonyms, translations, and symbols - with multiple ways to refer to the same medicine.

The taxonomies will be provided in English, and researchers will be able to search the spelling of Chinese characters as part of the new taxonomies.

BUCM teaches TCM and is also involved in the Cochrane Collaboration, a global independent network of researchers, professionals, patients, carers and individuals interested in health.

As part of the Cochrane China Group, BUCM is dedicated to publishing high evidence-based practices.

Embase, Elsevier's biomedical literature database, allows researchers to access the biomedical research they need quickly and accurately.

It has over 32m records from almost 8,300 published journals. Embase contains a wide range of comprehensive, evidence-based medicine, drug and medical device efficacy studies.

Elsevier, part of RELX Group, helps institutions and professionals progress science, advance healthcare, and improve performance. It provides digital solutions and tools in the areas of strategic research management, R and D performance, clinical decision support, and professional education.

The company publishes over 2,500 digitized journals,, more than 35,000 e-book titles, and many iconic reference works.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 1, 2018
Words:340
Previous Article:Edico Genome Teams Up with InterSystems to Improve Clinical NGS Workflows.
Next Article:Durect Initiates Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters